振东制药（300158）1月23日披露业绩预告称，2025年度归属于上市公司股东的净利润亏损22000万元— 28000万元。 针对业绩变动，振东制药称主要系三方面原因。 其一，公司生产经营活动正常开展，但由于行业政策与市场环境变化等因素，部分产品的销量或价格出 现下滑，致使该部分产品贡献的利润有所下降。 其二，报告期内，受整体市场供需关系影响，部分中药材品种价格延续下跌态势，导致公司中药材业务 仍处于亏损状态。 其三，报告期内，预计非经常性损益对公司归属于上市公司股东的净利润的影响约为1500万元，主要为 政府补助和理财收益等项目影响。上年同期，非经常性损益对归属于上市公司股东的净利润的影响金额 为-64222.40万元。 ...

报告期内，预计非经常性损益对公司归属于上市公司股东的净利润的影响约为1500万元，主要为政府补 助和理财收益等项目影响。上年同期，非经常性损益对归属于上市公司股东的净利润的影响金额为- -6.42亿元。 公告中提到，业绩变动的原因主要是由于行业政策与市场环境变化，部分产品的销量或价格下滑，导致 相关利润下降。此外，整体市场供需关系影响了部分中药材品种价格的延续下跌，使得公司的中药材业 务仍处于亏损状态。 近日，振东制药（300158）发布公告称，预计2025年度归母净利润约亏损2.2亿元至2.8亿元，较上年同 期亏损13.29亿元有所改善。 ...

Core Insights - The hair medical service industry is experiencing significant growth driven by increasing consumer focus on appearance and aesthetics, with a projected market size of 270.8 billion yuan by 2025 and 296.8 billion yuan by 2026 [1][9] Industry Definition and Classification - Hair medical services address various hair issues such as hair loss, alopecia, and scalp conditions, categorized into surgical hair transplant services and non-surgical hair care services [2][4] Market Size and Growth - The hair medical service market in China is expected to grow to 270.8 billion yuan by 2025, with hair transplant services accounting for 238.9 billion yuan (88.22%) and hair care services for 31.9 billion yuan (11.78%) [9] - By 2026, the market is projected to reach 296.8 billion yuan, with hair transplant services at 259.6 billion yuan (87.47%) and hair care services at 37.2 billion yuan (12.53%) [9] Industry Chain - The upstream of the hair medical service industry includes equipment for hair transplants and hair care, while the midstream consists of service providers such as hair transplant and care institutions. The downstream involves marketing through various online and offline channels targeting hair loss patients [10] Industry Development History - The hair medical service industry in China has evolved through four stages: technology introduction, market emergence, standardized development, and rapid growth, spanning over 100 years [11] Competitive Landscape - The market is characterized by a mix of national chain private hair transplant institutions, medical beauty institutions, public hospital transplant departments, and other non-chain private institutions, with national chains holding about 25% market share [12] - Key players include Yonghe Medical, Dama Micro-needle Transplant, and others in the hair transplant sector, while companies like SanSheng Pharmaceutical and Zhendong Pharmaceutical dominate the hair care market [12] Company Profiles - Yonghe Medical, established in 2010, is the largest one-stop hair service provider in China, offering a tiered service system to cater to diverse patient needs [14][15] - Zhendong Pharmaceutical is a major player in the hair care market, with its Minoxidil product leading in market share and recognized for its safety and effectiveness [13] Future Outlook - The rise of the beauty economy is shifting the focus of hair medical services from merely restoring function to enhancing aesthetics, leading to a broader demand for comprehensive hair management solutions [16][17] - The industry is expected to evolve towards a more integrated, personalized, and routine approach to hair health management, with an emphasis on professional training and standardized treatment processes [17]

（编辑 丛可心） 证券日报网讯 1月23日，振东制药发布公告称，公司预计2025年归属于上市公司股东的净利润亏损22， 000万元至28，000万元，上年同期亏损132，856.39万元；扣除非经常性损益后的净利润亏损23，500万 元至29，500万元，上年同期亏损68，633.99万元。 ...

格隆汇1月23日丨振东制药(300158.SZ)公布，预计2025年亏损22,000万元—28,000万元，扣非亏损23,500 万元---29,500万元。1、报告期内，公司生产经营活动正常开展，但由于行业政策与市场环境变化等因 素，部分产品的销量或价格出现下滑，致使该部分产品贡献的利润有所下降。2、报告期内，受整体市 场供需关系影响，部分中药材品种价格延续下跌态势，导致公司中药材业务仍处于亏损状态。3、报告 期内，预计非经常性损益对公司归属于上市公司股东的净利润的影响约为1,500万元，主要为政府补助 和理财收益等项目影响。上年同期，非经常性损益对归属于上市公司股东的净利润的影响金额 为-64,222.40万元。 ...

振东制药（300158）(300158.SZ)披露2025年度业绩预告，公司预计归属于上市公司股东的净亏损2.2亿 元至2.8亿元;扣除非经营性损益后的净亏损2.35亿元至2.95亿元。 ...

人民财讯1月23日电，振东制药（300158）1月23日公告，公司预计2025年度归母净利亏损2.2亿元—2.8 亿元，上年同期亏损13.29亿元。报告期内，公司生产经营活动正常开展，但由于行业政策与市场环境 变化等因素，部分产品的销量或价格出现下滑，致使该部分产品贡献的利润有所下降。受整体市场供需 关系影响，部分中药材品种价格延续下跌态势，导致公司中药材业务仍处于亏损状态。 ...

南财智讯1月23日电，振东制药发布年度业绩预告，预计2025年全年归属于上市公司股东的净利润为亏 损22000万元—28000万元；预计2025年全年归属于上市公司股东的扣除非经常性损益的净利润为亏损 23500万元—29500万元，。1、报告期内，公司生产经营活动正常开展，但由于行业政策与市场环境变 化等因素，部分产品的销量或价格出现下滑，致使该部分产品贡献的利润有所下降。2、报告期内，受 整体市场供需关系影响，部分中药材品种价格延续下跌态势，导致公司中药材业务仍处于亏损状态。 3、报告期内，预计非经常性损益对公司归属于上市公司股东的净利润的影响约为1500万元，主要为政 府补助和理财收益等项目影响。上年同期，非经常性损益对归属于上市公司股东的净利润的影响金额 为-64,222.40万元。 ...

山西振东制药股份有限公司 2025 年度业绩预告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 一、本期业绩预计情况 （一）业绩预告期间：2025年1月1日至2025年12月31日 （二）预计的业绩：亏损 证券代码：300158 证券简称：振东制药 公告编号：2026-001 1、报告期内，公司生产经营活动正常开展，但由于行业政策与 市场环境变化等因素，部分产品的销量或价格出现下滑，致使该部分 产品贡献的利润有所下降。 2、报告期内，受整体市场供需关系影响，部分中药材品种价格 延续下跌态势，导致公司中药材业务仍处于亏损状态。 3、报告期内，预计非经常性损益对公司归属于上市公司股东的 净利润的影响约为1,500万元，主要为政府补助和理财收益等项目影 响。上年同期，非经常性损益对归属于上市公司股东的净利润的影响 金额为-64,222.40万元。 （三）业绩预告情况表 | 项 | 目 | | 本报告期 | | 上年同期 | | | --- | --- | --- | --- | --- | --- | --- | | 归属于上市公司股东的 | | 亏损：22,00 ...

Core Viewpoint - Wang Zheyu, the Vice President and Board Secretary of Zhendong Pharmaceutical, submitted his resignation due to a job transfer, although he will continue to hold other positions within the company. His early departure raises questions about potential changes in company plans [1][5]. Group 1: Career Progression - Wang Zheyu's career trajectory shows a clear path from the pharmaceutical industry to capital investment and back to pharmaceuticals, indicating a strong understanding of both sectors [1]. - From 2012 to 2017, he gained experience in the pharmaceutical industry at Yabao Pharmaceutical, where he learned to analyze the industry and participate in project investments [2]. - He later became an Investment Director at Songshan Capital, focusing on identifying and managing investments in the pharmaceutical and consumer sectors [2]. - Between 2017 and 2022, he worked at Tianfeng Securities and then at Lujizhi Technology Group, where he transitioned from an investor to a company manager, successfully leading the company to the Hong Kong stock market [3]. Group 2: Role at Zhendong Pharmaceutical - In April 2022, Wang Zheyu returned to the pharmaceutical sector as the General Manager of the Strategy Department at Zhendong Pharmaceutical, overseeing legal affairs and strategic planning [3]. - By May 2023, he was promoted to Vice President and Board Secretary, taking on significant responsibilities as the company's spokesperson and compliance officer [4]. Group 3: Company Challenges and Developments - During Wang Zheyu's tenure as Board Secretary, Zhendong Pharmaceutical faced a significant arbitration case related to product quality issues, resulting in a total compensation payment of 500 million yuan to Langdi Pharmaceutical [6][7]. - The company also received a regulatory letter from the Shanxi Securities Regulatory Bureau regarding undisclosed fund occupation by the controlling shareholder, amounting to 51.3 million yuan [8][9]. - Despite these challenges, Zhendong Pharmaceutical's market value increased from 58.67 billion yuan in May 2023 to 60.73 billion yuan by January 2026 [10][11]. Group 4: Financial Performance - For the first three quarters of the previous year, Zhendong Pharmaceutical reported revenues of 2.215 billion yuan, a year-on-year decrease of 2.42%, and a net profit of 20.36 million yuan, down 49.25% [16]. - However, the company showed a strong performance in the third quarter, achieving revenues of 758 million yuan and a net profit of 124.33 million yuan, representing a year-on-year increase of 31.34% [16].